Sales or Revenue 295.31 M
Industry Health Care/Life Sciences
1Y Sales Change -11.85%
Fiscal Year Ends December 31 Download Reports
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Board of Directors
|Name/Title||Current Board Membership|
Past Five Years Ending 12/31/2020 (Fiscal Year)
|Revenue+3827.65%||Net Income+36.50%||Earnings Per Share-4.61%|
|Capital Spending-17.62%||Gross Margin+78.52%||Cash Flow-60.59%|
Akebia Therapeutics Inc v Fibrogen, Inc & Astellas  EWHC 866 (Pat)
A multi-patent action concerning the use of an enzyme inhibitor to treat anaemia and related conditions. The patents in issue fell into two families – Family A & Family B – and included claims to classes of compounds and to single compounds.
Akebia sought revocation of the patents to clear the way for launch of its pharmaceutical product. The grounds for revocation included insufficiency and obviousness.
Fibrogen was the patentee and Astellas its exclusive licensee. Astellas counter-sued for infringement, alleging both literal infringement and infringement by equivalents.
Arnold LJ, who came down from the Court of Appeal to hear the case at first instance, held that the Family A patents involved inventive step but, to the extent that they covered classes of compounds, were insufficient. The Family B patents were obvious. He further held that certain claims of the Family A patents were infringed on a literal basis, but dismissed the infringement claim based on equivalence to the single compound. There was insufficient threat of infringement of the Family B patents.
Permission to appeal has been granted in respect of the findings of invalidity.
Points of interest include the Judge’s comments on the utility of primers, the instruction and cross examination of expert witnesses, infringement by equivalence and how to assess a threat of infringement based on the likelihood of future ‘off label’ prescribing
Iain Purvis QC, Piers Acland QC and Anna Edwards-Stuart represented Akebia. Kathryn Pickard represented Astellas
 EWHC 866 (Pat)
Akebia Therapeutics Inc
Exchange NASDAQ More
- Industry Biotechnology More
- Sector Healthcare More
- 11-50 Employees
- Based in Cambridge, Massachussets
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease.
Most Recent Annual Report
View Form 10K(HTML)
Akebia Therapeutics Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.Shipping Information
Please fill out the form below and click "Place Order" to complete your order.Request Information
Akebia Therapeutics Inc AKBA:NASDAQ
- Day High2.87
- Day Low2.79
- Prev Close2.81
- 52 Week High5.14
- 52 Week High Date02/08/21
- 52 Week Low2.09
- 52 Week Low Date10/30/20
- Market Cap490.46M
- Shares Out174.54M
- 10 Day Average Volume1.49M
- Dividend Yield-
- YTD % Change0.36
- EPS (TTM)-1.98
- P/E (TTM)-1.42
- Fwd P/E (NTM)-2.33
- EBITDA (TTM)-254.397M
- ROE (TTM)-109.96%
- Revenue (TTM)221.90M
- Gross Margin (TTM)31.22%
- Net Margin (TTM)-135.00%
- Debt To Equity (MRQ)55.50%
- Earnings Date11/03/2021
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
There is no recent news for this security.
There is no recent news for this security.
Akebia Therapeutics, Inc.
|Mr. John P. Butler MBA||CEO, Pres & Director||1.2M||N/A||1964|
|Mr. David A. Spellman||Sr. VP, CFO & Treasurer||591.06k||N/A||1977|
|Mr. Michel Dahan||Sr. VP & COO||655.14k||N/A||1979|
|Mr. Jason A. Amello||Exec. Officer||435.66k||N/A||1968|
|Mr. Dell Faulkingham||Sr. VP & Chief Commercial Officer||660.04k||N/A||1973|
|Dr. Steven Keith Burke||Sr. VP of R&D and Chief Medical Officer||681.87k||N/A||1961|
|Ms. Violetta Cotreau||Sr. VP, Chief Accounting Officer & Principal Accounting Officer||N/A||N/A||1973|
|Ms. Nicole R. Hadas||Sr. VP, Chief Legal Officer & Sec.||N/A||N/A||1973|
|Mr. Douglas Jermasek||VP of Marketing & Strategy||N/A||N/A||N/A|
|Ms. Tamara Dillon||Sr. VP of HR||N/A||N/A||N/A|
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10.The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy ofInstitutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
How many times can we fly to the Sun and back. Eighteen, if you admit, Slept like a baby. Perhaps he would still be asleep, but Leah raised her.
- Accurate reel
- Lifetime shed
- Gm trailer plug wiring diagram
- Badimo twitter
- Pegassi zentorno
- Vrbo durango colorado pet friendly
- Animal sketch
- Smith brothers 5000 vs 8000
I quickly dashed to the closet, put on the first panties I came across, just in case, they, of course, were not from the set for the transparent. Peignoir already put on, took a glass, in which I did not have time, as I usually did, to finish, in case they were caught, there will be a otmaz, they say, he went to the kitchen for water, and slipped into the corridor.
He quietly walked to the door to his mother's room, trying to pace so that, God forbid, some treacherous floorboard would not. Creak.